Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN)
The Phase IV study sponsored by Jinan Mental Hospital aims to evaluate the efficacy of Risperidone in improving the quality of life for patients with Alzheimer's Disease and Behavioral and Psychological Symptoms of Dementia (BPSD). Given the increasing prevalence of Alzheimer's disease globally, this study addresses a significant unmet need in dementia care. The collaboration with Johnson & Johnson, the manufacturer of Risperidone, suggests a strategic interest in reinforcing the drug's market position. The findings may influence prescribing practices and reimbursement policies, particularly in regions with high Alzheimer's prevalence. The study's outcomes could also provide valuable data for potential label expansions or additional indications for Risperidone, enhancing its commercial viability.
Indication: Dementia
Modality: small molecule
Target: Dopamine D2 receptor antagonist (Risperidone) with potential modulation of serotonin receptors.
Sponsor: Jinan Mental Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Dopamine D2 receptor antagonist (Risperidone) with potential modulation of serotonin receptors.
View original source fields
Condition raw: Dementia, Alzheimer's Disease
Condition normalized: Dementia, Alzheimer's Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dopamine D2 receptor antagonist (Risperidone) with potential modulation of serotonin receptors.
Target normalized: Dopamine D2 receptor antagonist (Risperidone) with potential modulation of serotonin receptors.